18F-FLT PET imaging as a biomarker for risk assessment in meningiomas


  • 3’-deoxy-3’-18F-Fluorothymidine (18F-FLT) positron emission tomography (PET) is a promising imaging biomarker for predicting the likelihood of tumor progression in meningiomas.

Why this matters

  • Meningiomas are the most frequently detected primary intracranial extra-axial tumors in adults, and are usually observed with an assumption of being benign or irradiated without tissue diagnosis.

  • Because meningiomas often present in areas that are not safely accessible by surgery or biopsy, a non-invasive biomarker for predicting tumor growth could help identify patients who would benefit from immediate treatment while avoiding overtreatment in patients who could remain under observation.